Available Trials

Acute Myeloid Leukemia |  Advance Solid Tumor |  Brain |  Breast |  Breast Cancer and Bone Metastases |  Chronic Lymphocytic Leukemia |  Colorectal |  Diffuse Large B-cell Lymphoma |  EGFR mutated, cMET amplified, locally advanced/metastatic non-small cell lung cancer |  Gastric/Gastroesophageal Junction |  Gynecological |  Head and Neck |  Hodgkin Lymphoma |  Lung cancer |  Mantle Cell Lymphoma |  Melanoma |  Met CRPC Men with Metastatic Castration Resistant Prostate Cancer  |  Met NSCLC |  Met SCCHN Metastatic Squamous Cell Carcinoma of the head and neck |  Metastatic Castration Resistant Prostate Cancer  |  Metastic Malignancies |  Multiple Myeloma |  Myelodysplastic Syndrome |  Nasopharyngeal |  Neuroedocrine |  Non-Hodgkin's Lymphoma |  Non-Small Cell Lung Cancer |  NSCL/Gast |  NSCLC |  Ovarian |  Prostate |  SCLC |  Solid Tumor Lung |  Solid Tumor Lymphoma. |  Solid Tumors |  Squamous |  TNBC Triple-Negative Breast Cancer | 

Acute Myeloid Leukemia

Advance Solid Tumor

Brain

Breast

  • 16-228
  • 16-128
  • 15-146
  • 14-192
  • ML25749
  • USOR 14-192
    A PHASE I, MULTICENTER, OPEN-LABEL, TWO-PART, DOSE-ESCALATION STUDY OF RAD1901 IN POSTMENOPAUSAL WOMEN WITH ADVANCED ESTROGEN RECEPTOR POSITIVE AND HER2-NEGATIVE BREAST CANCER
  • USOR 14-052
    A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects with Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
  • USO 13-204
    Phase 1 Study of Mifepristone in Combination with Eribulin in Patients with Locally Advanced/Metastatic Breast Cancer with a Dose Expansion Cohort in Patients with Triple Negative Breast Cancer
  • USOR 13-053
    A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies
  • Galena/Genentech ML25749
    Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence
  • Side-Out Foundation SO-BCA-002 Side-Out 2
    A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA-Seq, and Exome Sequencing of Patients’ Tumors to Find Potential Targets and Select Treatments for Patients with Metastatic Breast Cancer

Breast Cancer and Bone Metastases

Chronic Lymphocytic Leukemia

  • USOR 13-177
    A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Colorectal

Diffuse Large B-cell Lymphoma

  • ProNAi Theapeutics PNT2258-03-DLBCL “WOLVERINE”
    A PHASE II STUDY OF PNT2258 IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
  • USO 13-060
    A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma
  • USOR 13-056
    A phase 2 study of brentuximab vedotin in combination with standard of care treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [RCHOP]) as front-line therapy in patients with diffuse large B-cell lymphoma (DLBCL)

EGFR mutated, cMET amplified, locally advanced/metastatic non-small cell lung cancer

Gastric/Gastroesophageal Junction

  • PCYC-1128-CA
  • 13-053
  • USOR 13-053
    A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies

Gynecological

Head and Neck

  • AstraZeneca 4193C00003 “CONDOR”
    A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • AstraZeneca D4193C00001 “HAWK”
    A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Hodgkin Lymphoma

  • ADCT-301-001
  • ADCT-301-001
  • ADC Therapeutics ADCT-301-001
    A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
  • Astellas 4132-CL-0001
    An Open-Label, Dose-Escalation/Expansion Phase 1 Study of ASP4132 Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma
  • 11-282
    A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Lung cancer

Mantle Cell Lymphoma

  • Astellas 4132-CL-0001
    An Open-Label, Dose-Escalation/Expansion Phase 1 Study of ASP4132 Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma
  • USO 13-060
    A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma

Melanoma

  • USOR 13-079
    A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma

Met CRPC Men with Metastatic Castration Resistant Prostate Cancer

Met NSCLC

Met SCCHN Metastatic Squamous Cell Carcinoma of the head and neck

Metastatic Castration Resistant Prostate Cancer

Metastic Malignancies

Multiple Myeloma

Myelodysplastic Syndrome

Nasopharyngeal

Neuroedocrine

Non-Hodgkin's Lymphoma

  • ADCT-301-001
  • ADCT-301-001
  • ADC Therapeutics ADCT-301-001
    A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
  • Astellas 4132-CL-0001
    An Open-Label, Dose-Escalation/Expansion Phase 1 Study of ASP4132 Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma
  • USO 13-060
    A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma

Non-Small Cell Lung Cancer

  • 16-156
  • 16-006
  • Clovis CO-1686-033
    A Phase 1/2 study of the safety and efficacy of rociletinib when administered in combination with trametinib in patients with activating EGFR mutation-positive advanced or metastatic non-small cell lung cancer (NSCLC)
  • AstraZeneca D5160C00019
    A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Rosuvastatin (a Sensitive BCRP Substrate) in Patients with EGFRm Positive NSCLC whose disease has Progressed on an EGFR TKI
  • USOR 14-114 “TIGER 1”
    A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Clovis CO-1686-019 “TIGER 2”
    A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) Harboring the T790M Resistance Mutation
  • Incyte INCB 18424-266
    A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non–Small Cell Lung Cancer That Is Stage IIIB With Pleural/Pericardial Effusion, Stage IV, or Recurrent
  • Novartis LDK378A2303
    A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients with ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib

NSCL/Gast

NSCLC

Ovarian

Prostate

SCLC

Solid Tumor Lung

Solid Tumor Lymphoma.

Solid Tumors

Squamous

  • AstraZeneca 4193C00003 “CONDOR”
    A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

TNBC Triple-Negative Breast Cancer